2 years ago

Verastem Receives Orphan Drug Designation from FDA for VS-5584 in Mesothelioma

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ:VSTM), dedicated to discovering as well as developing drugs to treat cancer by the specific killing involving cancer stem cells, today announced in which VS-5584 offers received orphan drug designation coming from the actual U.S. Meals and also Drug Administration pertaining to use in the treatment method regarding mesothelioma. the designation was developed to encourage the particular development associated with drugs that might offer significant benefit in order to patients suffering via uncommon diseases.